The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Evinova will operate as a separate health-tech business within AstraZeneca
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The company has raised US$4.5 million in funding for its AI operating system
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
Subscribe To Our Newsletter & Stay Updated
